Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) introduced right now that CEO Renée Aguiar-Lucander has web bought 50,000 shares by Calliditas’ warrant program 2019/2022. Following the brand new subscription for shares, her shareholding within the firm will quantity to 643,000 frequent shares.
The vast majority of the members of administration who’re eligible choice holders in this system have right now web bought shares by way of the warrant program 2019/2022, which incorporates 422,500 warrants and might be exercised as much as and together with December 31, 2022. To partially finance the share purchases, the choice holders in this system, together with the CEO and eligible members of administration, have offered shares. This sale, which consisted of 352,500 shares, was made right now in a block transaction.
” I’m excited concerning the firm’s improvement and success so far, together with the promising begin to our commercialization of TARPEYO within the US and the numerous progress of the franchise equivalent to regulatory submitting in China, industrial launch in Europe and the addition of a accomplice in Japan. I sit up for persevering with constructing worth in our lead program backed by our thrilling late-stage pipeline, which additionally has the potential of serious worth creation in 2023,” mentioned Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.
All shares within the warrant program 2019/2022 have been subscribed for, and Calliditas will obtain SEK 31.5 million in money.
For additional data, please contact:
Marie Galay, IR Supervisor, Calliditas
Tel.: +44 79 55 12 98 45, e mail: [email protected]
The knowledge was despatched for publication, by the company of the Calliditas contact individual set out above, on December 20, 2022 at 9:15 p.m. CET.
About Calliditas
Calliditas Therapeutics is a industrial stage biopharma firm based mostly in Stockholm, Sweden targeted on figuring out, growing and commercializing novel therapies in orphan indications, with an preliminary concentrate on renal and hepatic ailments with important unmet medical wants. Calliditas’ lead product, Nefecon, has been granted accelerated approval by the FDA beneath the commerce title TARPEYO® and conditional advertising authorization by the European Fee beneath the commerce title Kinpeygo®. Kinpeygo is being commercialized within the European Union Member States by Calliditas’ accomplice, STADA Arzneimittel AG. Moreover, Calliditas is conducting a Part 2b/3 scientific trial in main biliary cholangitis and a Part 2 proof-of-concept trial in head and neck most cancers with its NOX inhibitor product candidate, setanaxib. Calliditas’ frequent shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq World Choose Market (ticker: CALT). Go to www.calliditas.com for additional data.
Ahead-Wanting Statements
This press launch comprises forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements relating to Calliditas’ technique, commercialization efforts, enterprise plans, regulatory submissions, scientific improvement plans and focus. The phrases “could,” “will,” “might,” “would,” “ought to,” “count on,” “plan,” “anticipate,” “intend,” “consider,” “estimate,” “predict,” “mission,” “potential,” “proceed,” “goal,” and related expressions are supposed to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Any forward-looking statements on this press launch are based mostly on administration’s present expectations and beliefs and are topic to quite a few dangers, uncertainties, and vital elements that will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, any associated to Calliditas’ enterprise, operations, , market acceptance of Kinpeygo/TARPEYO, security or efficacy of Kinpeygo/TARPEYO, scientific trials, provide chain, technique, objectives and anticipated timelines, competitors from different biopharmaceutical firms, and different dangers recognized within the part entitled “Threat Components” in Calliditas’ reviews filed with the Securities and Alternate Fee. Calliditas cautions you to not place undue reliance on any forward-looking statements, which communicate solely as of the date they’re made. Calliditas disclaims any obligation to publicly replace or revise any such statements to mirror any change in expectations or in occasions, circumstances, or circumstances on which any such statements could also be based mostly, or that will have an effect on the probability that precise outcomes will differ from these set forth within the forward-looking statements. Any forward-looking statements contained on this press launch signify Calliditas’ views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date.
https://information.cision.com/calliditas-therapeutics/r/calliditas-ceo-acquires-shares-through-the-exercise-of-calliditas–warrant-program-2019-2022,c3688063
https://mb.cision.com/Primary/16574/3688063/1750220.pdf
(c) 2022 Cision. All rights reserved., supply Press Releases – English
